Toxicology

Jaya Biosciences Presents Promising Preclinical Data in Alzheimer’s Disease at the 20th Annual WORLDSymposium™ 2024

Retrieved on: 
Monday, February 12, 2024
SAN, Toxicology, Research, APP, Plaque, PPT1, Life, Haploinsufficiency, Science Advisory Board, CNS, GUSB, Patient, GALC, Gene, IDUA, Q&A, NAGLU, IND, AAV

SOUTH SAN FRANCISCO, Calif., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Jaya Biosciences, Inc. (“JayaBio” or “the Company”), a privately held early-stage life-sciences company developing CNS-directed gene therapies to address unmet needs in genetically defined neurodegeneration, reported non-clinical data at the 20th Annual WORLDSymposium™, a leading research conference on lysosomal diseases. During a late-breaking news platform presentation, Jaya Biosciences’ scientific founder, Prof. Mark Sands, reported preliminary human genetic analysis suggesting that heterozygous loss-of-function mutations in lysosomal enzyme genes are enriched in Alzheimer’s patients, as well as preclinical efficacy results in the animal model of Alzheimer’s disease (AD) for JB111, the Company’s lead therapy.

Key Points: 
  • “We are thrilled to showcase a new paradigm for the treatment of genetically defined neurodegeneration at the 20th WORLDSymposium™,” said Pawel Krysiak, President and CEO of JayaBio.
  • “The preclinical data we presented demonstrate a tremendous promise of targeting PPT1 haploinsufficiency in Alzheimer’s disease.
  • Heterozygosity of five different lysosomal enzyme genes (PPT1, NAGLU, GALC, IDUA, GUSB) significantly affects amyloid precursor protein (APP) processing and favors pro-amyloidogenic pathway.
  • CNS-directed, AAV-mediated gene therapy significantly increases the life span and improves cognitive function of 5xFAD/PPT1+/- mice.

Chemical Insights Research Institute Scientist Honored for Technical Innovation and STEM Education

Retrieved on: 
Monday, February 12, 2024
Research, General Health, Environmental Health, Oncology, Other Education, University, Other Manufacturing, Environment, Education, Science, Chemicals, Plastics, Health, Manufacturing, Engineering, Toxicology, MIT, EMPOWER, Mentorship, Public health, Georgia State University, RTX, Harvard University, Mathematics, Conference, The Council, Environmental toxicology, CIRI, Natural environment, Information technology, Student, Management

Dr. Christa Wright of Chemical Insights Research Institute (CIRI) of UL Research Institutes, will receive the Outstanding Technical Contribution in Industry Award at the 2024 Black Engineer of the Year Award (BEYA) STEM (science, technology, engineering and mathematics) Conference on Feb 17, 2024, in Baltimore, Md.

Key Points: 
  • Dr. Christa Wright of Chemical Insights Research Institute (CIRI) of UL Research Institutes, will receive the Outstanding Technical Contribution in Industry Award at the 2024 Black Engineer of the Year Award (BEYA) STEM (science, technology, engineering and mathematics) Conference on Feb 17, 2024, in Baltimore, Md.
  • She earned a Ph.D. in Environmental Systems and Environmental Toxicology and a Masters in Cancer Biology from North Carolina A&T State University.
  • Dr. Wright developed and led a National Institute of Environmental Health Sciences funded STEM summer program, called EMPOWER from 2018-2021 during her tenure at Georgia State University.
  • “Christa is extremely passionate about STEM education and research,” said Dr. Marilyn Black, Vice President and Senior Technical Advisor at CIRI.

First PFAS "Forever Chemicals" Consumer-Initiated Blood Test with Physician Consult Launches on questhealth.com

Retrieved on: 
Monday, February 12, 2024
Water supply, Physician, Orthostatic hypertension, B2B, Poison, Doctor of Pharmacy, Agency, Vaccine, Risk, Health, National academy, Firefighter, History, Quest Diagnostics, Organization, PFAS, Pre-eclampsia, Patient, Toxicology, Kidney, Science, CDC, DGX, Birth weight, Environment, Cosmetics

"Our PFAS blood test is based on the latest science and aligns with several facets of new CDC guidance as well as recommendations from the National Academies of Sciences, Engineering, and Medicine.

Key Points: 
  • "Our PFAS blood test is based on the latest science and aligns with several facets of new CDC guidance as well as recommendations from the National Academies of Sciences, Engineering, and Medicine.
  • Not everyone needs a PFAS test, but people at high risk of elevated exposure may benefit from greater access to the insights provided by this novel test."
  • It is the first PFAS blood test available as a consumer-initiated test with physician consult to report a sum of PFAS chemicals based on level of health risks identified by the National Academies of Sciences, Engineering, and Medicine (NASEM).
  • The Quest test aligns with several recommendations from NASEM on PFAS testing, including:
    Quantifying levels of several specific PFAS chemicals identified for potential health risks.

Multi-Billion Opportunities in the US Clinical Laboratory Tests Market, More than $109 Billion Revenue by 2029 - Arizton

Retrieved on: 
Thursday, February 8, 2024
Insurance, Pharmacy, Laboratory, Health, Specialization, Growth, COVID-19, Diagnosis, Telehealth, Community, OPKO Health, Labcorp, Sonic Healthcare, Compound annual growth rate, Hospital, Endocrinology, Patient, Community health center, Antibody, Quest Diagnostics, Consumer, Toxicology, Pharmaceutical industry

Most US clinical laboratory test companies offer routine or specialized clinical diagnostic testing services or both depending on their scientific expertise, technologies, innovations, and relevant regulations.

Key Points: 
  • Most US clinical laboratory test companies offer routine or specialized clinical diagnostic testing services or both depending on their scientific expertise, technologies, innovations, and relevant regulations.
  • Therefore, the competitive landscape in the country for the clinical laboratory tests market is highly localized and challenging.
  • Overall, the U.S. clinical laboratory tests market witnessed dynamic shifts driven by advancements in specialty testing, the prominence of hospital-based laboratories, and the continued demand for clinical and immunochemistry tests.
  • Competitive landscape analysis: A thorough examination of the market's competitive landscape is presented, including detailed information about companies operating in the US clinical laboratory tests market.

Multi-Billion Opportunities in the US Clinical Laboratory Tests Market, More than $109 Billion Revenue by 2029 - Arizton

Retrieved on: 
Thursday, February 8, 2024
Insurance, Pharmacy, Laboratory, Health, Specialization, Growth, COVID-19, Diagnosis, Telehealth, Community, OPKO Health, Labcorp, Sonic Healthcare, Compound annual growth rate, Hospital, Endocrinology, Patient, Community health center, Antibody, Quest Diagnostics, Consumer, Toxicology, Pharmaceutical industry

Most US clinical laboratory test companies offer routine or specialized clinical diagnostic testing services or both depending on their scientific expertise, technologies, innovations, and relevant regulations.

Key Points: 
  • Most US clinical laboratory test companies offer routine or specialized clinical diagnostic testing services or both depending on their scientific expertise, technologies, innovations, and relevant regulations.
  • Therefore, the competitive landscape in the country for the clinical laboratory tests market is highly localized and challenging.
  • Overall, the U.S. clinical laboratory tests market witnessed dynamic shifts driven by advancements in specialty testing, the prominence of hospital-based laboratories, and the continued demand for clinical and immunochemistry tests.
  • Competitive landscape analysis: A thorough examination of the market's competitive landscape is presented, including detailed information about companies operating in the US clinical laboratory tests market.

Phenovista Appoints Pharmaceutical Industry Veteran and Toxicology Expert Eckhard von Keutz, PhD to its Scientific Advisory Board

Retrieved on: 
Thursday, February 8, 2024
Biotechnology, Health, Science, Pharmaceutical, Research, Cell proliferation, Bayer, Workflow, Senior, Research fellow, Toxicology, Doctor of Philosophy, Liver, Cardiotoxicity, Management

Phenovista , a life sciences services company developing and implementing multiplexed, high content imaging-based phenotypic assays for target validation, lead optimization, and mechanism of action studies, today announced the appointment of Eckhard von Keutz to its Scientific Advisory Board.

Key Points: 
  • Phenovista , a life sciences services company developing and implementing multiplexed, high content imaging-based phenotypic assays for target validation, lead optimization, and mechanism of action studies, today announced the appointment of Eckhard von Keutz to its Scientific Advisory Board.
  • Most recently, Dr. von Keutz served as the Senior Vice President and Head of Translational Science (Preclinical and Early Clinical Development) at Bayer Pharmaceuticals.
  • “We are excited to welcome Eckhard to our Scientific Advisory Board,” said James Evans, PhD, Chief Executive Officer of Phenovista.
  • “Phenovista’s ability to support and de-risk mission-critical R&D decision-making is unmatched in the industry,” said Dr. von Keutz.

Arrowhead Pharmaceuticals Reports Fiscal 2024 First Quarter Results

Retrieved on: 
Tuesday, February 6, 2024
Infectious Diseases, Diabetes, Genetics, Clinical Trials, Cardiology, Biotechnology, Health, Pharmaceutical, Oncology, DSM-IV codes, CTA, Obesity, Retirement, Patient, PIN, Head, IgA nephropathy, Marketing, Idiopathic pulmonary fibrosis, RNA interference, GLP, ARO, Arrowhead, Identified, Webcast, Liver, Pharmacy, Toxicology, Completeness, Pharmaceutical industry

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2024 first quarter ended December 31, 2023.

Key Points: 
  • Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2024 first quarter ended December 31, 2023.
  • The Company is hosting a conference call today, February 6, 2024, at 4:30 p.m.
  • A replay of the webcast will be available approximately two hours after the conclusion of the call.
  • Once registered, you will receive the dial-in number and a personalized PIN code that will be required to access the call.

CytoTronics Reveals Pixel System to Monitor Live Cell Function at an Unprecedented Scale for Cell Biology Applications

Retrieved on: 
Monday, February 5, 2024
Research, General Health, Pharmaceutical, Data Management, Technology, Semiconductor, Science, Biotechnology, Stem Cells, Other Technology, Other Science, Health, Epithelium, Laboratory automation, Cell biology, Electronics, Cell, B cell, Harvard University, Electrophysiology, USD, Exhibition, Data science, Medium (website), Drug discovery, Computer, Pixel, Metabolism, SLAS, Toxicology, Data collection, Television

Pixel assesses live cell function at single-cell resolution, allowing scientists to simultaneously monitor cell viability, morphology, electrophysiology, metabolism, and more while generating electrical ‘images’ with single-cell spatial resolution.

Key Points: 
  • Pixel assesses live cell function at single-cell resolution, allowing scientists to simultaneously monitor cell viability, morphology, electrophysiology, metabolism, and more while generating electrical ‘images’ with single-cell spatial resolution.
  • Pixel delivers simultaneous multi-modal, high-resolution readouts in 96- or 384-well plates, enabling cell monitoring and data collection at unprecedented scale.
  • It’s widely applicable for in vitro cell biology applications including drug discovery, from target validation to toxicology screening.”
    CytoTronics’ early-access program for Pixel Primo empowers cell biologists to unlock applications that were previously inaccessible.
  • The early-access program includes applications for endothelial and epithelial cells, cancer cell biology, mechanism of action/toxicology, stem cell biology, cardiac function, and neural function.

Sai Life Sciences augments DMPK capabilities to ace large-scale collaborations

Retrieved on: 
Thursday, February 1, 2024
Met, Pharmacokinetics, Growth, Peptide, Absorption, Pharmacology, Immunohistochemistry, Safety, IDD, TK, Appetite, Drug discovery, Proteolysis targeting chimera, DMPK, Automation, ADME, Metabolite, Metabolism, Toxicology, Development, Biology

HYDERABAD, India, Feb. 01, 2024 (GLOBE NEWSWIRE) -- To offer global big pharma clients cutting-edge, end-to-end drug metabolism and pharmacokinetics (DMPK) services, Sai Life Sciences, a global Contract Research, Development & Manufacturing Organization (CRO-CDMO) , has expanded its DMPK capabilities .

Key Points: 
  • HYDERABAD, India, Feb. 01, 2024 (GLOBE NEWSWIRE) -- To offer global big pharma clients cutting-edge, end-to-end drug metabolism and pharmacokinetics (DMPK) services, Sai Life Sciences, a global Contract Research, Development & Manufacturing Organization (CRO-CDMO) , has expanded its DMPK capabilities .
  • Making the announcement, Krishna Kanumuri, CEO & Managing Director, Sai Life Sciences, said, “The focus of innovator companies on diversifying their supply chains bodes well for Indian CROs-CDMOs like ours.
  • Sauri Gudlavalleti, Chief Operating Officer said, “The latest expansion of DMPK capabilities augments our integrated drug discovery (IDD) offerings.
  • Sai Life Sciences also has plans to invest in niche areas such as peptides, oligos and large molecules to strengthen its discovery capabilities.

PMI and BAT Announce Global Patent Settlement

Retrieved on: 
Friday, February 2, 2024
Tobacco, Retail, Smoke, COVID-19, Philip Morris International, Security (finance), Public, Life, Research, British American Tobacco, Intellectual property, BAT, Annual report, Marketing, PMI, IQOS, Food, Privacy, Information, Swedish Match, American Tobacco Company, Sale, Patent, Smoking, Toxicology, ZYN, Form, Tobacco harm reduction, Woman

Philip Morris International Inc (PMI) (NYSE: PM) is pleased to announce that it has reached a global settlement with British American Tobacco p.l.c.

Key Points: 
  • Philip Morris International Inc (PMI) (NYSE: PM) is pleased to announce that it has reached a global settlement with British American Tobacco p.l.c.
  • (BAT) that resolves all ongoing patent infringement litigation between the parties related to our heated tobacco and vapor products.
  • Patent protection is a critical component of the innovation driving PMI’s strategies and the company welcomes this settlement as the best path forward for its business plans.
  • The settlement includes non-monetary provisions between PMI and BAT that resolve all ongoing global patent infringement litigation, encompassing all related injunctions and exclusion orders, and prevents future claims against current heated tobacco and vapor products.